Nuclear export modulates TDP-43 phase transitions and cytoplasmic aggregation

This study identifies nuclear export as a critical regulator of TDP-43 phase transitions, demonstrating that inhibiting nuclear export promotes a protective liquid-liquid phase separation state within the nucleus, thereby preventing pathogenic cytoplasmic aggregation associated with ALS.

The Gist

The Big Picture: A Sticky Protein Gone Wrong

Imagine your cells are bustling cities. Inside these cities, there is a very important worker protein called TDP-43. Under normal conditions, TDP-43 lives in the "City Hall" (the nucleus), where it helps manage the city's blueprints (RNA). It's a busy, social protein that likes to hang out in liquid-like droplets, chatting with other molecules and getting work done.

However, in diseases like ALS (Lou Gehrig's disease) and FTD, something goes wrong. TDP-43 gets confused, loses its ability to read the blueprints, and moves out of City Hall into the streets (the cytoplasm). Once it's out there, it stops being a liquid droplet and turns into a hard, sticky concrete block. These blocks pile up, clog the streets, and eventually kill the city's workers (neurons).

The big question scientists have been asking is: What makes TDP-43 turn from a helpful liquid into a deadly concrete block?

The Discovery: The "Export" Gatekeeper

This paper acts like a detective story. The researchers used two main tools to find the culprit:

1. Chemical Screening: They tested thousands of drugs to see which ones changed how TDP-43 behaved.
2. Genetic Screening: They turned off thousands of genes to see which ones were responsible for TDP-43's behavior.

The Main Character: XPO1 (The Export Gate)
The most exciting discovery is a cellular "gatekeeper" protein called XPO1. Think of XPO1 as the security guard at the exit door of City Hall. Its job is to let things out of the nucleus and into the streets.

• The Problem: The researchers found that when XPO1 is working too hard (or when TDP-43 is forced out too quickly), TDP-43 rushes into the cytoplasm. Once there, without the right environment, it hardens into those deadly concrete blocks.
• The Solution: When the researchers blocked XPO1 (shut the gate), TDP-43 stayed inside the nucleus. Instead of turning into concrete, it stayed in a healthy, liquid state. It formed larger, rounder droplets that were still flexible and could move around.

The Analogy:
Imagine TDP-43 is a group of people at a party.

• Normal State: They are dancing in a liquid-like circle in the living room (nucleus).
• The "Export" Effect: If you force them all out the front door into the freezing cold (cytoplasm) too fast, they huddle together, freeze, and turn into a solid, unmoving ice sculpture (aggregation).
• The Fix: If you keep the door closed (block XPO1), they stay inside the warm living room. They might get a bit crowded and form a bigger circle, but they stay liquid, warm, and alive.

Other Factors in the Mix

The study also found other "city managers" that influence whether TDP-43 stays liquid or turns to concrete:

1. The Construction Crew (RNA Splicing): TDP-43 loves to read blueprints. If you stop the construction crew from finishing the blueprints (inhibiting RNA splicing), TDP-43 gets stuck holding the unfinished plans. This actually keeps it in a liquid state, preventing it from hardening.
2. The Trash Collectors (Proteasome): If the trash collectors stop working (proteasome inhibition), the "concrete blocks" get bigger and harder because the cell can't clean them up.
3. The Bodyguards (Chaperones): Proteins like HSP90 act like bodyguards, helping TDP-43 fold correctly. If you remove the bodyguards, TDP-43 gets confused and clumps up.

The "Brain in a Dish" Test

To make sure this wasn't just a theory, the researchers tested it on brain organoids. These are tiny, 3D models of human brains grown in a lab from stem cells. They used cells from a patient with an ALS mutation.

• The Result: When they treated these tiny brains with a drug that blocks the XPO1 gate (keeping TDP-43 inside), the "concrete blocks" (toxic, phosphorylated TDP-43) disappeared. The cells looked healthier.

Why This Matters

This research changes how we think about treating ALS and FTD.

For a long time, scientists thought the only way to stop the disease was to stop TDP-43 from clumping together. But this paper suggests a different strategy: Control the traffic.

If we can tweak the "export gate" (XPO1) to keep TDP-43 inside the nucleus where it belongs, or at least keep it in a liquid state rather than a solid one, we might be able to stop the disease before the concrete blocks form. It's like fixing the traffic light at the city exit to prevent a traffic jam that turns into a pile-up.

In short: The key to stopping TDP-43 from becoming toxic might not be to destroy it, but to keep it inside the house where it stays fluid and happy.

Technical Summary

1. Problem Statement

TAR DNA-binding protein 43 (TDP-43) is an RNA-binding protein essential for RNA metabolism. Its mislocalization from the nucleus to the cytoplasm and subsequent aggregation into solid inclusions are hallmarks of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). While TDP-43 is known to undergo liquid-liquid phase separation (LLPS) to form nuclear condensates, the cellular mechanisms governing the transition of TDP-43 from a dynamic liquid state to rigid, pathological solid aggregates remain poorly defined. Specifically, it is unclear how cellular pathways modulate this phase behavior and how nuclear transport defects contribute to the formation of cytoplasmic toxic aggregates.

2. Methodology

The authors employed a multi-faceted approach combining chemical genetics, genome-wide screening, live-cell imaging, and advanced organoid models:

• Cell Model: They utilized a DLD1 cell line stably expressing a doxycycline-inducible, RNA-binding defective TDP-43 mutant (2KQ) tagged with Clover (GFP). This mutant mimics ALS-associated variants and rapidly forms nuclear "anisosomes" (spherical condensates with a TDP-43 shell and HSP70 core).
• Chemical Genetic Screen: A high-throughput screen was performed using the LOPAC1280 small molecule library (1,280 compounds) on induced TDP-43 2KQ cells to identify drugs that modulate anisosome number and size.
• Genome-wide siRNA Screen: An unbiased screen targeting 21,404 human genes was conducted to identify genetic regulators of TDP-43 phase separation. Hits were filtered using STRING protein network analysis and re-validated.
• Live-Cell Imaging & Biophysics:
  • FRAP (Fluorescence Recovery After Photobleaching): Used to assess the fluidity (liquid vs. gel/solid state) of TDP-43 condensates.
  • Time-lapse Microscopy: Used to observe fusion events and dynamic changes in condensate morphology.
• Semi-Permeabilized Cell Assay: A novel in vitro system using Streptolysin O (SLO) to permeabilize cell membranes, allowing the study of TDP-43 phase transitions in a controlled environment with cytosolic add-backs (cytosol, ATP, GTP) and RNase treatments.
• Organoid Validation: A 3D brain organoid model derived from iPSCs carrying the endogenous ALS-associated K181E mutation in TARDBP was used to validate findings in a disease-relevant context. Organoids were treated with the XPO1 inhibitor KPT-276 and stained for phosphorylated TDP-43 (p-TDP-43).

3. Key Contributions & Results

A. Identification of Phase Modulators

The screens identified four major cellular pathways regulating TDP-43 phase behavior:

1. RNA Splicing: Inhibition (e.g., with Pladienolide-B) reduced anisosome number but increased size, maintaining a liquid state.
2. Protein Translation: Inhibition (e.g., with Cycloheximide) similarly stabilized liquid condensates.
3. Proteostasis: Proteasome inhibition (e.g., Bortezomib) and HSP90 inhibition (e.g., Tripterin/Geldanamycin) converted liquid anisosomes into enlarged, static, gel-like/solid structures. Deubiquitinase inhibition reduced anisosome numbers, likely by enhancing clearance.
4. Nuclear Export: This was identified as a critical regulator.

B. Nuclear Export (XPO1) as a Phase Switch

The study revealed a bidirectional role for the nuclear export receptor XPO1:

• Inhibition of XPO1 (e.g., Leptomycin B, KPT-276):
  • Reduced the number of anisosomes but increased their size.
  • Condensates remained in a liquid state (high mobility in FRAP) and exhibited fusion events.
  • Mechanistically, this stabilization was shown to be RNA-dependent; treating permeabilized cells with RNase dissolved the enlarged anisosomes.
• Overexpression of XPO1:
  • Induced the formation of fewer, irregular, enlarged puncta.
  • Crucially, these puncta appeared in the cytoplasm (~30% of cells) and exhibited gel-like/solid properties (no fluorescence recovery in FRAP).
  • This suggests that excessive nuclear export drives TDP-43 toward a pathological, aggregated state.

C. Mechanistic Insights from Semi-Permeabilized Cells

The semi-permeabilized assay demonstrated that:

• Permeabilization dissolves anisosomes due to the loss of cytosolic factors and ATP.
• Re-addition of cytosol and energy sources restores puncta formation.
• LMB-treated cells (which have enlarged anisosomes) maintained stability even after permeabilization, but this stability was abolished by RNase, confirming that nuclear export inhibition stabilizes TDP-43 condensates by increasing the availability of nuclear RNA.

D. Validation in Disease Models

In iPSC-derived brain organoids bearing the K181E mutation:

• Endogenous p-TDP-43 (a marker of pathological aggregation) accumulated in the cytoplasm.
• Treatment with the XPO1 inhibitor KPT-276 significantly reduced cytoplasmic p-TDP-43 accumulation without altering total TDP-43 levels.
• This confirms that inhibiting nuclear export can mitigate the formation of pathological TDP-43 aggregates in a human-relevant model.

4. Significance

• Mechanistic Framework: The study establishes a direct link between nuclear transport defects and TDP-43 phase transitions. It proposes that nuclear export acts as a "molecular switch": reduced export favors a protective liquid phase (retaining TDP-43 in the nucleus), while enhanced or dysregulated export promotes the transition to toxic, solid cytoplasmic aggregates.
• RNA Dependence: It highlights that the phase behavior of TDP-43 is tightly coupled to RNA availability and splicing intermediates, suggesting that RNA metabolism and nucleocytoplasmic transport are mechanistically linked in regulating condensate dynamics.
• Therapeutic Implications: The findings suggest that modulating nuclear export (specifically inhibiting XPO1) could be a viable therapeutic strategy to prevent the liquid-to-solid transition of TDP-43, thereby reducing neurotoxicity in ALS and FTD.
• Model System: The development of the semi-permeabilized cell assay provides a powerful tool for dissecting the biochemical requirements of TDP-43 phase transitions in a controlled setting.

In summary, this paper defines nuclear export as a key regulator of TDP-43 phase dynamics, demonstrating that its inhibition stabilizes TDP-43 in a non-toxic liquid state within the nucleus, while its dysregulation drives the formation of pathological cytoplasmic aggregates.